Immunocore Holdings PLC Sponsored ADR $IMCR Shares Bought by Legal & General Group Plc

Legal & General Group Plc grew its stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 18.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 149,333 shares of the company’s stock after acquiring an additional 23,577 shares during the period. Legal & General Group Plc’s holdings in Immunocore were worth $5,183,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC grew its stake in Immunocore by 334.3% in the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after acquiring an additional 974,463 shares during the period. Bellevue Group AG grew its stake in Immunocore by 14.5% in the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock worth $101,608,000 after acquiring an additional 354,973 shares during the period. Armistice Capital LLC grew its stake in Immunocore by 21.5% in the 3rd quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock worth $29,936,000 after acquiring an additional 146,000 shares during the period. Candriam S.C.A. grew its stake in shares of Immunocore by 100.1% during the 3rd quarter. Candriam S.C.A. now owns 269,729 shares of the company’s stock valued at $9,799,000 after buying an additional 134,950 shares during the period. Finally, Marshall Wace LLP grew its stake in shares of Immunocore by 425.8% during the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock valued at $4,601,000 after buying an additional 118,728 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IMCR has been the subject of a number of analyst reports. Mizuho set a $38.00 price objective on shares of Immunocore in a research report on Thursday, February 19th. Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group cut shares of Immunocore from a “buy” rating to a “hold” rating and decreased their price objective for the company from $48.00 to $33.00 in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immunocore currently has an average rating of “Moderate Buy” and an average price target of $56.71.

Immunocore Stock Performance

Immunocore stock opened at $28.29 on Monday. The company has a 50 day moving average price of $29.77 and a 200 day moving average price of $32.65. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $27.56 and a 52 week high of $40.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -51.44 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The firm had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same quarter last year, the business posted $0.10 EPS. The company’s revenue was up 13.6% on a year-over-year basis. Research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

About Immunocore

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.